Various Genetic Disorders
Genetic disorders targetable by gene silencing (e.g., Familial Amyloid Neuropathies, Hemophilia A)
PreclinicalActive
Key Facts
Indication
Genetic disorders targetable by gene silencing (e.g., Familial Amyloid Neuropathies, Hemophilia A)
Phase
Preclinical
Status
Active
Company
About Oncogenuity
Oncogenuity is a preclinical-stage biotech leveraging a proprietary oligonucleotide platform to develop gene-silencing therapies that act at the DNA level. Its lead asset targets the historically 'undruggable' KRAS G12D mutation prevalent in pancreatic, colorectal, and other cancers, with a significant estimated market opportunity. The company, founded in 2018 and based in Cambridge, USA, is also exploring the platform's utility against COVID-19 and various genetic disorders, positioning it in the high-potential but high-risk RNA and gene therapy sector.
View full company profile